Last updated: 22 July 2019 at 6:40am EST

Michael D Hooven Net Worth




The estimated Net Worth of Michael D Hooven is at least $6.51 Milión dollars as of 5 May 2017. Michael Hooven owns over 10,000 units of Atricure Inc stock worth over $1,803,618 and over the last 19 years Michael sold ATRC stock worth over $4,705,059.

Michael Hooven ATRC stock SEC Form 4 insiders trading

Michael has made over 15 trades of the Atricure Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Michael exercised 10,000 units of ATRC stock worth $95,000 on 5 May 2017.

The largest trade Michael's ever made was selling 142,268 units of Atricure Inc stock on 30 March 2015 worth over $2,960,597. On average, Michael trades about 12,319 units every 134 days since 2005. As of 5 May 2017 Michael still owns at least 67,049 units of Atricure Inc stock.

You can see the complete history of Michael Hooven stock trades at the bottom of the page.



What's Michael Hooven's mailing address?

Michael's mailing address filed with the SEC is 6033 SCHUMACHER PARK DRIVE, , WEST CHESTER, OH, 45069.

Insiders trading at Atricure Inc

Over the last 19 years, insiders at Atricure Inc have traded over $52,789,242 worth of Atricure Inc stock and bought 666,621 units worth $5,937,195 . The most active insiders traders include Scott William Drake, Group I, Llc Donoghue Danie... a Management Group Viii L L C.... On average, Atricure Inc executives and independent directors trade stock every 24 days with the average trade being worth of $548,410. The most recent stock trade was executed by Maggie Yuen on 15 August 2024, trading 3,500 units of ATRC stock currently worth $84,245.



What does Atricure Inc do?

atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.



Complete history of Michael Hooven stock trades at Atricure Inc

Človek
Trans.
Transakcia
Celková cena
Michael D Hooven
Riaditeľ
Využitie opcie $95,000
5 May 2017
Michael D Hooven
Riaditeľ
Predaj $2,960,597
30 Mar 2015
Michael D Hooven
Riaditeľ
Predaj $1,154,640
31 Dec 2014
Michael D Hooven
Riaditeľ
Kúpa $8,036
14 Sep 2012
Michael D Hooven
Riaditeľ
Kúpa $8,181
13 Sep 2012
Michael D Hooven
Riaditeľ
Kúpa $8,165
12 Sep 2012
Michael D Hooven
Riaditeľ
Kúpa $8,221
11 Sep 2012
Michael D Hooven
Riaditeľ
Kúpa $8,687
10 Sep 2012
Michael D Hooven
Riaditeľ
Kúpa $8,359
7 Sep 2012
Michael D Hooven
Riaditeľ
Predaj $35,070
13 Mar 2012
Michael D Hooven
Riaditeľ
Predaj $420,000
13 Jun 2011
Michael D Hooven
Riaditeľ
Predaj $134,752
10 Nov 2010
Michael D Hooven
Riaditeľ
Kúpa $99,456
9 Jun 2008
Michael D Hooven
Riaditeľ
Využitie opcie $85,657
3 Jan 2007
Michael D Hooven
Riaditeľ
Využitie opcie $8,289
14 Dec 2005


Atricure Inc executives and stock owners

Atricure Inc executives and other stock owners filed with the SEC include: